Lilly USA Overview
- Year Founded
-
1876
- Status
-
Public
- Employees
-
50,000
- Stock Symbol
-
LLY
- Investments
-
249
- Share Price
-
$1.35K
- (As of Thursday Closing)
Lilly USA General Information
Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact Information
Website
www.lilly.comCorporate Office
- Lilly Corporate Center
- Indianapolis, IN 46285
- United States
Corporate Office
- Lilly Corporate Center
- Indianapolis, IN 46285
- United States
Lilly USA Timeline
Lilly USA Stock Performance
As of 19-Nov-2026, Lilly USA’s stock price is $1.35K. Its current market cap is $1.2T with 891M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.35K | $1.38K | $850.51 - $1.48K | $1.2T | 891M | 2.58M | $30.85 |
Lilly USA Financials Summary
As of 30-Sep-2026, Lilly USA has a trailing 12-month revenue of $86.5B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,077,329,433 | 994,509,358 | 721,953,716 | 571,131,575 |
| Revenue | 86,462,000 | 65,179,000 | 45,043,000 | 34,124,000 |
| EBITDA | 37,998,000 | 27,728,000 | 14,447,000 | 8,081,000 |
| Net Income | 27,580,000 | 20,640,000 | 10,590,000 | 5,240,000 |
| Total Assets | 148,072,000 | 112,476,000 | 78,715,000 | 64,006,300 |
| Total Debt | 49,503,000 | 42,503,000 | 33,644,000 | 25,225,300 |
Lilly USA Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lilly USA Comparisons
Industry
Financing
Details
Lilly USA Competitors (31)
One of Lilly USA’s 31 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Pfizer | Corporation | New York, NY | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Lilly USA Patents
Lilly USA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2026906711-A0 | Combination therapies for treating cancer | Pending | 31-Jul-2026 | ||
| CA-246920-S | Box | Active | 27-Jun-2025 | ||
| WO-2026231470-A1 | Injection device | Pending | 02-May-2025 | ||
| WO-2026231928-A1 | Bolus perfusion culture methods | Pending | 30-Apr-2025 | ||
| WO-2026226900-A2 | Methods for producing one arm antibody molecules and methods for producing engineered cysteine antibody conjugation | Pending | 25-Apr-2025 | C07K16/00 |
Lilly USA Signals
Lilly USA Investments & Acquisitions (249)
Lilly USA’s most recent deal was a Merger/Acquisition with Calytrix Bio for . The deal was made on 16-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Calytrix Bio | 16-Nov-2026 | Merger/Acquisition | Drug Discovery | ||
| SRTD Biotech | 09-Nov-2026 | Seed Round | Drug Discovery | ||
| T-Therapeutics | 05-Nov-2026 | Early Stage VC | Drug Discovery | ||
| BigHat Biosciences | 24-Sep-2026 | Later Stage VC | Drug Discovery | ||
| AtaiBeckley | 09-Sep-2026 | Merger/Acquisition | Biotechnology |
Lilly USA ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
20.34 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Lilly USA Exits (60)
Lilly USA’s most recent exit was on 05-May-2026 from Cabaletta Bio. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cabaletta Bio | 05-May-2026 | Completed |
|
||
| Sunbird Bio | 16-Oct-2024 | Completed |
|
||
| Aktis Oncology | 20-Sep-2024 | Completed |
|
||
| Elektrofi | 08-Aug-2024 | Completed |
|
||
| Ionetix | 07-Aug-2024 | Later Stage VC | Completed |
|
Lilly USA Affiliates
Subsidiaries (17)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kelonia | Boston, MA | 2021 | |
| Centessa Pharmaceuticals | Altrincham, United Kingdom | 2019 | |
| Ajax Therapeutics | New York, NY | 2019 | |
| 4E Therapeutics | Austin, TX | 2019 | |
| Verve Therapeutics | Boston, MA | 2018 |
Lilly USA FAQs
-
When was Lilly USA founded?
Lilly USA was founded in 1876.
-
Where is Lilly USA headquartered?
Lilly USA is headquartered in Indianapolis, IN.
-
What is the size of Lilly USA?
Lilly USA has 50,000 total employees.
-
What industry is Lilly USA in?
Lilly USA’s primary industry is Drug Discovery.
-
Is Lilly USA a private or public company?
Lilly USA is a Public company.
-
What is Lilly USA’s stock symbol?
The ticker symbol for Lilly USA is LLY.
-
What is the current stock price of Lilly USA?
As of 19-Nov-2026 the stock price of Lilly USA is $1.35K.
-
What is the current market cap of Lilly USA?
The current market capitalization of Lilly USA is $1.2T.
-
What is Lilly USA’s current revenue?
The trailing twelve month revenue for Lilly USA is $86.5B.
-
Who are Lilly USA’s competitors?
Amgen, Bristol-Myers Squibb, AbbVie, Pfizer, and Merck & Co. are some of the 31 competitors of Lilly USA.
-
What is Lilly USA’s annual earnings per share (EPS)?
Lilly USA’s EPS for 12 months was $30.85.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process